Neurogene (NASDAQ:NGNE) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Posted by Brian Himes on May 12th, 2026

Neurogene (NASDAQ:NGNE – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.09), Zacks reports.

Neurogene Stock Performance

NASDAQ NGNE traded up $0.65 during trading on Tuesday, reaching $31.54. The company’s stock had a trading volume of 103,482 shares, compared to its average volume of 167,081. The firm has a market cap of $492.65 million, a price-to-earnings ratio of -7.44 and a beta of 1.69. Neurogene has a twelve month low of $14.65 and a twelve month high of $37.27. The business’s fifty day moving average price is $23.48 and its 200-day moving average price is $22.06.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NGNE shares. Lifesci Capital assumed coverage on shares of Neurogene in a research report on Monday, January 26th. They issued an “outperform” rating and a $50.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research report on Tuesday, January 13th. Canaccord Genuity Group dropped their price target on Neurogene to $180.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Finally, Guggenheim started coverage on shares of Neurogene in a research note on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.00.

Get Our Latest Stock Report on Neurogene

Insiders Place Their Bets

In other Neurogene news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the transaction, the insider directly owned 30,497 shares in the company, valued at approximately $634,642.57. The trade was a 18.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christine Mikail Cvijic sold 9,600 shares of Neurogene stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $31.25, for a total transaction of $300,000.00. Following the completion of the transaction, the chief financial officer owned 93,640 shares in the company, valued at approximately $2,926,250. This represents a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 20,442 shares of company stock worth $525,622. 9.92% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Virtus Investment Advisers LLC increased its stake in shares of Neurogene by 128.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 12,716 shares of the company’s stock worth $262,000 after acquiring an additional 7,138 shares during the period. Logos Global Management LP acquired a new position in shares of Neurogene during the fourth quarter worth about $4,017,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Neurogene during the fourth quarter worth about $575,000. Trexquant Investment LP increased its stake in shares of Neurogene by 9.7% during the fourth quarter. Trexquant Investment LP now owns 43,323 shares of the company’s stock worth $892,000 after acquiring an additional 3,840 shares during the period. Finally, Blair William & Co. IL increased its stake in shares of Neurogene by 15.4% during the fourth quarter. Blair William & Co. IL now owns 163,655 shares of the company’s stock worth $3,371,000 after acquiring an additional 21,835 shares during the period. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Company Profile

(Get Free Report)

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.